Kercheville Advisors’s AbbVie ABBV Stock Holding History

Kercheville Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$356K	Buy	1,416 +1	+0.1%	+$215	0.11%	82
2026 Q1	$308K	Sell	1,415 -48	-3%	-$10.6K	0.1%	84
2025 Q4	$319K	Buy	1,463 +1	+0.1%	+$228	0.08%	91
2025 Q3	$339K	Buy	1,462 +39	+3%	+$7.94K	0.1%	82
2025 Q2	$264K	Buy	1,423 +202	+17%	+$37.5K	0.09%	83
2025 Q1	$256K	Hold	1,221	–	–	0.1%	73
2024 Q4	$217K	Buy	+1,221	New	+$224K	0.08%	81
2024 Q2	–	Sell	-6,900	Closed	-$1.26M	–	85
2024 Q1	$1.26M	Buy	+6,900	New	+$1.19M	0.59%	36
2022 Q2	–	Sell	-6,570	Closed	-$1.06M	–	95
2022 Q1	$1.06M	Sell	6,570 -900	-12%	-$131K	0.5%	43
2021 Q4	$1.01M	Buy	+7,470	New	+$882K	0.44%	47

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Kercheville Advisors's ABBV Position: Q2 2026 in Review

Kercheville Advisors increased its AbbVie (ABBV) stake by 0.07% in Q2 2026, buying an estimated $215 and bringing the position to 1,416 shares worth $356K. The position accounts for 0.11% of the portfolio, ranked #82.

Kercheville Advisors first reported a position in ABBV in Q4 2021 and has held it in 10 quarters since. The position peaked at $1.26M in Q1 2024. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Kercheville Advisors held 1,416 shares of AbbVie worth $356K as of Q2 2026.
Kercheville Advisors bought 1 AbbVie share in Q2 2026, an estimated $215.
AbbVie made up 0.11% of Kercheville Advisors's portfolio in Q2 2026, its #82 holding.
Kercheville Advisors first reported a position in AbbVie in Q4 2021 and has held it in 10 quarters since.
Kercheville Advisors's AbbVie position peaked at $1.26M in Q1 2024.
4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Kercheville Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.